1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
2 Ettinger DS, Aisner DL, Wood DE et al. NCCN guidelines insights: Non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16: 807–21.
3 Tani N, Yabuki M, Komuro S, Kanamaru H. Characterization of the enzymes involved in the vitro metabolism of amrubicin hydrochloride. Xenobiotica 2005; 35: 1121–33.
4 Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998; 89: 1067–73.
5 Kurata T, Okamoto I, Tamura K, Fukuoka M. Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs 2007; 25: 499–504.
6 Ogawa M. Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 1999; 125: 134–40.
7 Kaira K, Sunaga N, Tomizawa Y et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 2010; 69: 99–104.
8 Yoshioka H, Katakami N, Okamoto H et al. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol 2017; 28: 285–91.
9 Barret JM, Calsou P, Larsen AK, Salles B. A cisplatin- resistant murine leukemia cell line exhibits increased topoisomerase II activity. Mol Pharmacol 1994; 46: 431–6.
10 Murphy AJ, Hughes CA, Barrett C et al. Low-level TOPO2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res 2007; 67: 2893–8.
11 Fritz P, Cabrera CM, Dippon J et al. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: A retrospective study. Breast Cancer Res 2005; 7: R374–84.
12 Kaufmann SH, Karp JE, Jones RJ et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994; 83: 517–30.
13 Biesaga B, Niemiec J, Ziobro M, Wysocka J, Kruczak A. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy. Breast 2011; 20: 338–50.
14 Miura Y, Kaira K, Sakurai R et al. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin. Lung Cancer 2018; 115: 42–8.
15 Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave- processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357–63.
16 Gerdes J, Li L, Schlueter C et al. Immunobiochemical and molecular biologic characterization of the cell proliferation- associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867–73.
17 Jakobsen JN, Sørensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer 2013; 79: 1–7.
18 Giaccone G, van Ark-Otte J, Scagliotti G et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1995; 1264: 337–46.
19 Kreipe H, Alm P, Olsson H, Hauberg M, Fischer L, Parwaresch R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 1993; 142: 651–7.
20 Sun G, Wang S, Wang Y. Expressions of Topo IIα and Ki67 in breast cancer and its clinicopathologic features and prognosis. Pak J Med Sci 2019; 35: 715–20.
21 Iz_ycka-Świeszewska E, Lipska-Ziętkiewicz BS, Adamkiewicz-Droz_yn´ska E et al. Proliferation index revisited in neuroblastic tumors. Folia Neuropathol 2014; 52: 243–52.
22 Sundov D, Caric A, Mrklic I et al. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Diagn Pathol 2013; 8: 21.
23 Shimizu K, Kaira K, Tomizawa Y et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer. Br J Cancer 2014; 110: 2030–9.
24 Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter1 exession in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98: 742–8.
25 Matin B, Paesmans M, Mascaux C et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis. Br J Cancer 2004; 91: 2018–25.
26 Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–8.
27 Simon R, Atefy R, Wagner U et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003; 107: 764–72.
28 Washiro M, Ohtsuka M, Kimura F et al. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: A potential chemotherapeutic target. J Cancer Res Clin Oncol 2008; 134: 793–801.
29 Ferrandina G, Petrillo M, Carbone A et al. Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients. Br J Cancer 2008; 98: 1910–5.
30 Wong N, Yeo W, Wong WL et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009; 124: 644–52.
31 Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I et al. Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin’s lymphoma. Clin Cancer Res 2008; 14: 1759–66.
32 Li X, Liu Y, Chen W et al. TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget 2014; 5: 9498–513.
33 Nakopoulou L, Lazaris AC, Kavantzas N et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000; 68: 137–43.
34 Depowski PL, Rosenthal S, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase IIalpha expression in breast cancer: Correlation with outcome variables. Mod Pathol 2000; 13: 542–7.
35 Kasahara K, Fujiwara Y, Sugimoto Y et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 1992; 84: 113–8.
36 Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992; 52: 1666–74.
37 Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8: 1061–7.
38 Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S. Topo2alpha protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. Br J Cancer 2010; 103: 1794–800.
39 Fry AM, Chresta CM, Davies SM et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell line. Cancer Res 1991; 51: 6592–5.
40 Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M. Immunohischemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 1998; 77: 1469–73.
41 Guinee DG Jr, Holden JA, Benfield JR et al. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 1996; 78: 729–35.
42 Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009; 9: 327–37.
43 Bollimpelli VS, Dholaniya PS, Kondapi AK. Topoisomerase IIβand its role in different biological contexts. Arch Biochem Biophys 2017; 633: 78–84.
論文の公開元へ
